130 related articles for article (PubMed ID: 38287534)
1. Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides.
Fujimura T; Ohuchi K; Ikawa T; Kambayashi Y; Amagai R; Furudate S; Asano Y
Hematol Oncol; 2024 Jan; 42(1):e3244. PubMed ID: 38287534
[TBL] [Abstract][Full Text] [Related]
2. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9.
Vacca A; Moretti S; Ribatti D; Pellegrino A; Pimpinelli N; Bianchi B; Bonifazi E; Ria R; Serio G; Dammacco F
Eur J Cancer; 1997 Sep; 33(10):1685-92. PubMed ID: 9389934
[TBL] [Abstract][Full Text] [Related]
3. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene.
Tamer F; Gulekon A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):716-718. PubMed ID: 34102787
[TBL] [Abstract][Full Text] [Related]
4. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides.
Rasheed H; Tolba Fawzi MM; Abdel-Halim MR; Eissa AM; Mohammed Salem N; Mahfouz S
Am J Dermatopathol; 2010 Apr; 32(2):162-9. PubMed ID: 20051814
[TBL] [Abstract][Full Text] [Related]
6. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
8. Follicular mycosis fungoides: variability of a rare entity.
Roeschm A; Schleyer V; Landthaler M; Vogt T
Skinmed; 2005; 4(1):12-7. PubMed ID: 15654159
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
10. Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis.
Ginsburg E; Hennessy K; Mhaskar R; Seminario-Vidal L
Dermatol Ther; 2022 May; 35(5):e15418. PubMed ID: 35243730
[TBL] [Abstract][Full Text] [Related]
11. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
12. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas.
Gregoriou S; Rigopoulos D; Stamou C; Nikolaou V; Kontochristopoulos G
J Cutan Med Surg; 2013; 17(1):52-4. PubMed ID: 23364151
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
14. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of mycosis fungoides with PUVA and bexarotene].
Ortiz-Romero PL; Sánchez-Largo ME; Sanz H; García-Romero D; Rosales B; Valverde R; Arrue I; Polo I; Ruiz D; Fernández-Herrera J; Vanaclocha F
Actas Dermosifiliogr; 2006 Jun; 97(5):311-8. PubMed ID: 16956562
[TBL] [Abstract][Full Text] [Related]
17. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides.
Furudate S; Fujimura T; Kakizaki A; Kambayashi Y; Asano M; Watabe A; Aiba S
Exp Dermatol; 2016 Feb; 25(2):107-12. PubMed ID: 26441016
[TBL] [Abstract][Full Text] [Related]
18. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]